Related Experiment Videos
The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers.
1Clinical Research Division of Response Oncology, Inc., Memphis, Tennessee, USA.
The Oncologist
|July 1, 1999
Summary
Disseminating high-dose chemotherapy with peripheral blood stem cell support to community cancer centers offers economic and social benefits for patients. This expansion can improve access to vital treatments and accelerate clinical trial data generation.
Area of Science:
- Oncology
- Hematology
- Cancer Treatment
Background:
- High-dose chemotherapy (HDC) with peripheral blood stem cell (PBSC) support is a standard treatment for lymphoma, multiple myeloma, and some breast cancers.
- Current delivery is often limited to academic referral centers, creating access barriers for eligible patients.
Purpose of the Study:
- To present the rationale for implementing HDC with PBSC support in community cancer centers.
- To advocate for wider dissemination of this technology to practicing oncologists.
Main Methods:
- The manuscript reviews existing data and clinical experience regarding HDC with PBSC support.
- It analyzes the feasibility and benefits of delivering these treatments in an outpatient community setting.
Main Results:
- PBSC support enables safe and effective delivery of HDC regimens in an outpatient setting.
- Community-based delivery offers significant economic and social advantages for patients compared to referral centers.
Conclusions:
- Expanding HDC with PBSC support to community cancer centers improves patient access and cost-effectiveness.
- Wider community access can enhance clinical trial accrual and expedite the generation of crucial outcome data.